BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

AdnaGen 

Ostpassage 7

Langenhagen    D-30853  Germany
Phone: 49-0-511-725950-50 Fax: 49-0-511-725950-40


SEARCH JOBS




Industry
Biotechnology


Collaborations

Gen-Probe Incorporated (Acquired by Hologic)  In January 2005, Gen-Probe signed an agreement with AdnaGen, a private company based in Germany, to license AdnaGen's innovative "immunocapture" technology. The technology may help increase the accuracy of molecular diagnostic tests to detect prostate and other cancers, help determine the aggressiveness of these malignancies, and monitor responses to therapy.





 Company News
KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies 4/6/2011 10:10:30 AM
OncoVista Innovative Therapies, Inc. Sells AdnaGen Subsidiary: Total Sale Price Could Reach $65 Million Over Three Years When Milestones Achieved 11/11/2010 8:13:28 AM
OncoVista Innovative Therapies, Inc. Subsidiary AdnaGen Inks Exclusive Agreement with TATAA Molecular Diagnostics 1/26/2010 9:31:13 AM
LAB21 Limited to Provide AdnaGen's CE-Marked System for the Detection and Analysis of Circulating Tumor Cells (CTCs) in the United Kingdom and Ireland 8/10/2009 1:52:29 PM
OncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cells (CTCs) Diagnostic Technology in Women with High-Risk Locally Advanced Breast Cancer 7/24/2009 8:49:52 AM
AdnaGen and OncoVista Innovative Therapies, Inc., Announce the Issuance in the U.S. of a Key Patent Related to Technology for the Detection and Analysis of Circulating Tumor Cells 3/27/2009 8:43:10 AM
Sysmex Europe GmbH to Distribute Products for the Analysis of Circulating Tumor Cells in Different Tumor Entities Developed by AdnaGen, a Subsidiary of OncoVista Innovative Therapies, Inc. 1/29/2009 10:49:23 AM
OncoVista Innovative Therapies, Inc. Announces Submission of Request for Pre-IDE Determination Meeting with FDA for AdnaGen's AdnaTest Breast Cancer Device for Detection of Circulating Breast Tumor Cells 5/6/2008 8:29:16 AM
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer 4/11/2008 8:33:27 AM
OncoVista Increases Its Share in AdnaGen 12/17/2007 11:44:54 AM
12